CVNA has impressive momentum, with revenue up 42%. However, used-car economics are cyclical, and maintaining margins will be challenging.
LLY has the strongest structural growth story, driven by obesity and diabetes treatments. But at nearly 39x FY26 earnings, expectations are already demanding.
LHX offers a better balance between growth visibility and financial discipline. Its $53.2B backlog, 3.2x book-to-bill ratio and $1.3B quarterly free cash flow provide tangible support.
My strategy is to accumulate LHX gradually on weakness rather than chase the rally. The key metric I would watch is free cash flow conversion. Orders create expectations, but cash generation creates shareholder value.
@WallStreet_Tiger [财迷]
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
